Michael Rissler

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Xenofon Baraliakos, Laure Gossec, Effie Pournara et al. · Annals of the Rheumatic Diseases · 2020 · 188 citations · Full text

Medicine, Pharmacotherapy, Pain Management +14

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

Ulrich Mrowietz, H. Bachelez, A. David Burden et al. · Journal of the American Academy of Dermatology · 2019 · 142 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label <scp>OPTIMISE</scp> study

Kristian Reich, L. Puig, Jacek C. Szepietowski et al. · British Journal of Dermatology · 2019 · 64 citations

Medicine, Pharmacology, Pharmacotherapy +17

Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results

Matthias Augustin, E. Daudén, Ulrich Mrowietz et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 27 citations · Full text

Medicine, Dermatology, Pharmacotherapy +9

OP0235 SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL

Xenofon Baraliakos, Laura C. Coates, Laure Gossec et al. · Annals of the Rheumatic Diseases · 2019 · 25 citations

Medicine, Clinical Sciences, Pharmacotherapy +16